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made more efﬁcient.
Rationale: We examined our internal form auditing pro-
cesses as part of a cost reduction measure. Previously, we
were auditing 100% of all research and Transplant Essential
Data (TED) forms. Because of experienced data managers
and their continued training, our error rate was low
enough that reducing the breadth of the audit was
justiﬁed.
Best Practices: Most events occur in the ﬁrst year after
transplant. Therefore, we placed importance on this time
frame and varied the levels of importance on other forms
and used stratiﬁed sample auditing to cover them. This
allowed us to notice any trends in errors and provide
training. By selecting a percentage of all forms, we can
efﬁciently give feedback to data managers and provide
targeted training sessions.
Method:We are currently auditing 100% of research; post-
TEDs through 1 year. After 1 year we are utilizing the
stratiﬁed sample method for auditing post TEDs 2-6 years
at 50% and over 6 years at 25% per data manager. A data
manager may request a form be audited at any time point.
New employees are audited at 100% for their ﬁrst year.
We do routine education based on errors found on our
audits.
Outcome:We tracked our error rate over the past year and a
half and our calculated error rate was low enough to warrant
this change. Our current average error rate was 0.41 errors
per form. Through tracking audited forms, we found that we
saved 2.7 weeks or 107.3 hours per year of the auditor’s time.
Revising the auditing process has improved time, efﬁciency
and lowered the cost of auditing, while maintaining high
quality work with low error rates. The time saving of
approximately 3 weeks can be utilized in opening more
studies and other projects data coordinators are responsible
for.
Future: In phase two of time management, we have
streamlined our submission processes for auditing and
saving versions of forms. FormsNet3 (FN3) has proven that
we no longer need to do this and will in turn save valuable
drive space. The amount of time used to convert the form to
PDF, submit it, and correcting and resaving will also be saved
with the new process. We utilize the audit sheet to track
errors, communicate to datamanagers, andmake corrections
in FN3 e all without having to PDF a form. Additionally, er-
rors are sent and seen on a weekly basis and data managers
are given a week to make the corrections inFN3. We found
3.8 weeks per year of data managers’ time can be saved with
this change in process.BMT ADMINISTRATION/QUALITYFigure. BMT Readmission Rates - All Transplants.121
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Cleveland, OHPurpose: Hospital readmissions have been identiﬁed as an
indicator of poor quality care, are costly and largely pre-
ventable. As the focus of hospital readmissions becamemore
evident with the Affordable Care Act, our program began
discussions on how to reduce our 30 day readmission rate.
Since BMT programs are structured, process driven, and well
communicated, we felt this combination was ideal for iden-
tiﬁcation of weaknesses and areas for improvement to
reduce our rate.
Implementations: Our ﬁrst action was a real time multi-
disciplinary review of every 30 day readmission. The hope
was to identify contributing factors with input from all team
members that may not have been captured through docu-
mentation alone. Unfortunately no common themes were
identiﬁed. Other early on initiatives included:
 A hospital wide initiative was instituted for Nurse on
Call to contact all patients by phone within 48 hours of
discharge.
 We began utilizing our BMT PharmDs for allogeneic
discharge medication education. Unit nurses and nurse
coordinators still perform medication education; add-
ing the third clinician to create the individualized
medication schedule was a hope for increasing medi-
cation compliance.
 Our nurses began assessing autologous patients in
person within 48-72 hours of discharge instead of im-
mediate return to their local oncologist.
 All patients must be seen by a BMT physician within 5
days of discharge and have the appointment scheduled
prior to leaving the hospital.
 A longstanding effort is the post-transplant preparation
groupheldmonthlyprior todischarge.Multi-disciplinary
teammembersgather toeducatepatients and families on
what to expect after discharge.
A revived effort in reducing readmission was warranted
as the pressure to decrease our rate continued. The most
recent initiatives this year include:
 The creation of a same day BMT Acute Care Clinic. If
patients call with complaints, there are dedicated ap-
pointments where BMT physicians assess and treat
patients the same day.
 Midlevel providers and transplant nurse coordinators
began a twice a week huddle to discuss upcoming
discharges and identify potential hurdles to discharge.
 Mid-level providers began collecting a readmission
survey in attempt to gather more data surrounding the
Table
G. CSF Pilot Interim Analysis
No G. CSF
Median (Days)
G CSF
Control (Days)
Autologous (7 Cases, 10 Controls)
LOS 15 12
Neutrophil Engraftment 12 10
Allogeneic MAC (BM & PBPC)
(9 Cases, 9 Controls)
LOS 22 17
Neutrophil Engraftment 22 12
Allogeneic RIC (PBPC) (10 Cases,
10 Controls)
LOS 19 17
Neutrophil Engraftment 14 13
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perspective.
Conclusion: While our 30 day readmission rate has
decreased from 34.6 in 2009 to current rate of 23.5 (See
Figure), we still have work to do. The initial reduction cannot
be attributed to any particular effort(s) and we will continue
to be diligent and innovative in this endeavor. Some
readmissions are not preventable and fevers are a big
barrier. In the near future we hope to create a working
group with other institutions, focus on the patients who
are readmitted frequently, and develop criteria to deﬁne
what a true preventable readmission is.
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Introduction: Quality of care is a priority among patients,
providers, and accreditors in blood and marrow trans-
plantation (BMT), and has resulted in the need to develop
quality management systems. BMT programs can apply
quality frameworks such as the Model for Improvement,
which guide programs to set quality goals, and to develop
quality measurement and reporting strategies to ensure
progress toward those goals. We report on the systematic,
end-user-informed development of a set of quality in-
dicators, to be monitored and reported on in the context of a
quality framework at the Princess Margaret Cancer Centre
BMT program.
Methods: This involved three phases: 1) Evidence Review
(database and grey literature search for quality indicators
used in BMT); 2) Modiﬁed Delphi process, inwhich identiﬁed
indicator concepts were discussed to generate a list of broad
clinical categories, then prioritized via a staff survey; and 3)
investigation of the published literature for data standards
for these indicators.
Results: Evidence review generated 214 indicators, which
were categorized as Clinical (n¼139), Management-level
(n¼40), or Hospital-wide (n¼35). Only the Clinical in-
dicators were deemed meaningful for staff prioritization.
By merging like concepts, the 139 indicators were reduced
to 22 for inclusion in the prioritization exercise. Prioriti-
zation was achieved through an online survey sent to 152
clinical BMT staff. Respondents ranked indicators based on
their perceived clinical value as quality measures. Re-
spondents ranked “Survival” and “Treatment-related mor-
tality” most frequently in their top 3 choices. However, a
low survey response rate (35 of 152, or 23%) suggested a
lack of staff awareness of quality measurement, and a need
to coordinate staff education and creation of a quality
improvement culture to ensure success of such initiatives
in the future. Next, Management-level indicators were
pared down through discussion and consensus, generating
12 indicators to be developed for future reporting. The
Hospital-wide indicators, which were non-BMT-speciﬁc
but could be adapted for use in BMT quality measurement,
were mapped to corresponding Management-level and
Clinical indicators. Their existing measurement structures
may be useful in developing measurement strategies for
our BMT-speciﬁc quality indicators. Finally, workingtoward eventual implementation, all indicators were
assessed for any data standards mentioned in the litera-
ture. Our ﬁndings revealed a paucity of published data
standards for BMT quality indicators, highlighting a need
for more research in this ﬁeld.
Conclusions: Quality indicator development in BMT can be
undertaken systematically, but requires a concerted effort
from staff engagement to informatics infrastructure.
Currently, this area is challenged by a lack of published
development standards and implementation studies.123
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Background: The use of granulocyte colony stimulating
factor (G-CSF) to promote engraftment after hematopoietic
cell transplantation (HCT) remains controversial. Random-
ized controlled trials that showed a shorter duration of
neutropenia after G-CSF in autologous (auto) HCT recipients
were performed in an era when present supportive care
resources were not available. The use of G-CSF after allo-
geneic (allo) HCT is not established by randomized trials
and there is a concern that it may be associated with an
increased risk of graft-versus-host disease. G-CSF is a costly
drug and excluding its routine use may translate into sig-
niﬁcant cost savings for a transplant program. All inpatients
transplanted routinely receive G-CSF 480 mcg/day starting
day +5. We conducted a pilot study to evaluate if G-CSF
post-HCT could be safely omitted after autologous and
allogeneic HCT.
Methods: 2013 data was used as benchmarks for neutrophil
engraftment and hospital length of stay (LOS), calculated
from day 0. Three separate pilots were conducted for auto
HCT, myeloablative (MAC) allo and reduced-intensity (RIC)
allo HCT recipients. Eligibility criteria included sufﬁcient cell
dose for the product to be infused (PBSC 5.0 x106 CD34+
cells/kg for autos,2.0 x106/kg for allos or BM2.0x108 TNC/
kg). G-CSF was not administered prophylactically, but could
be given in clinical scenarios such as prolonged febrile
